These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 30343856)

  • 1. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
    Doherty M; Jenkins W; Richardson H; Sarmanova A; Abhishek A; Ashton D; Barclay C; Doherty S; Duley L; Hatton R; Rees F; Stevenson M; Zhang W
    Lancet; 2018 Oct; 392(10156):1403-1412. PubMed ID: 30343856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care.
    Latif ZP; Nakafero G; Jenkins W; Doherty M; Abhishek A
    Joint Bone Spine; 2019 May; 86(3):357-362. PubMed ID: 30394337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimising gout treatment: insights from a nurse-led cohort study.
    Rasmussen C; Larsen JW; Christensen HM; Larsen MB; Thomsen AM; Leishmann T; Kragh J; Nielsen GL
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38663881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nurse-led care is preferred over GP-led care of gout and improves gout outcomes: results of Nottingham Gout Treatment Trial follow-up study.
    Fuller A; Jenkins W; Doherty M; Abhishek A
    Rheumatology (Oxford); 2020 Mar; 59(3):575-579. PubMed ID: 31410473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.
    Mikuls TR; Cheetham TC; Levy GD; Rashid N; Kerimian A; Low KJ; Coburn BW; Redden DT; Saag KG; Foster PJ; Chen L; Curtis JR
    Am J Med; 2019 Mar; 132(3):354-361. PubMed ID: 30503879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
    Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
    BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials.
    Stamp LK; Frampton C; Morillon MB; Taylor WJ; Dalbeth N; Singh JA; Doherty M; Zhang W; Richardson H; Sarmanova A; Christensen R
    Lancet Rheumatol; 2022 Jan; 4(1):e53-e60. PubMed ID: 38288731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Easing the way to achieving target serum urate in people with gout: protocol for a non-inferiority randomised strategy trial using an allopurinol dosing model in Aotearoa/New Zealand (the Easy-Allo Study).
    Stamp L; Te Karu L; Reid S; Wright DFB; Frampton C; Tuitaupe VS; Dalbeth N
    BMJ Open; 2024 Aug; 14(8):e084665. PubMed ID: 39097306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout.
    Phang KF; Santosa A; Low BPL; Tan PSH; Khong ZW; Lim AYN; Teng GG; Tay SH
    Int J Rheum Dis; 2020 Aug; 23(9):1136-1144. PubMed ID: 32483906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
    Hill-McManus D; Marshall S; Soto E; Lane S; Hughes D
    Value Health; 2018 Dec; 21(12):1373-1381. PubMed ID: 30502780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
    Mackenzie IS; Ford I; Nuki G; Hallas J; Hawkey CJ; Webster J; Ralston SH; Walters M; Robertson M; De Caterina R; Findlay E; Perez-Ruiz F; McMurray JJV; MacDonald TM;
    Lancet; 2020 Nov; 396(10264):1745-1757. PubMed ID: 33181081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
    Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
    Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
    Coburn BW; Cheetham TC; Rashid N; Chang JM; Levy GD; Kerimian A; Low KJ; Redden DT; Bridges SL; Saag KG; Curtis JR; Mikuls TR
    Contemp Clin Trials; 2016 Sep; 50():106-15. PubMed ID: 27449546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of allopurinol and febuxostat for the management of gout.
    Jutkowitz E; Choi HK; Pizzi LT; Kuntz KM
    Ann Intern Med; 2014 Nov; 161(9):617-26. PubMed ID: 25364883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are Doctors the Best People to Manage Gout? Is There a Role for Nurses and Pharmacists?
    Latif Z; Abhishek A
    Curr Rheumatol Rep; 2018 Mar; 20(3):14. PubMed ID: 29516289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol.
    Day RO; Frensham LJ; Nguyen AD; Baysari MT; Aung E; Lau AYS; Zwar N; Reath J; Laba T; Li L; McLachlan A; Runciman WB; Buchbinder R; Clay-Williams R; Coiera E; Braithwaite J; McNeil HP; Hunter DJ; Pile KD; Portek I; WIlliams KM; Westbrook JI
    BMJ Open; 2017 Oct; 7(10):e017281. PubMed ID: 29042386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allopurinol Medication Adherence as a Mediator of Optimal Outcomes in Gout Management.
    Coburn BW; Bendlin KA; Sayles H; Meza J; Russell CL; Mikuls TR
    J Clin Rheumatol; 2017 Sep; 23(6):317-323. PubMed ID: 28816767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
    Robinson PC; Taylor WJ; Dalbeth N
    J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study.
    Rees F; Jenkins W; Doherty M
    Ann Rheum Dis; 2013 Jun; 72(6):826-30. PubMed ID: 22679303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Mackenzie IS; Hawkey CJ; Ford I; Greenlaw N; Pigazzani F; Rogers A; Struthers AD; Begg AG; Wei L; Avery AJ; Taggar JS; Walker A; Duce SL; Barr RJ; Dumbleton JS; Rooke ED; Townend JN; Ritchie LD; MacDonald TM;
    Lancet; 2022 Oct; 400(10359):1195-1205. PubMed ID: 36216006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.